Neoadjuvant chemotherapy is an important part of a systemic treatment of breast cancer, but problems of how to select sensitive drugs, develop individualized treatment plans and estimate the outcome, needs further research. In this paper, the authors address 4 perspectives: the significance of neoadjuvant chemotherapy and the patients suitable to receive it; the use of complete pathologic response as a prognostic marker; selection of drugs and treatment regimens and molecular classification-based neoadjuvant chemotherapy.